Amelogenin, an extracellular matrix protein, in the treatment of venous leg ulcers and other hard-to-heal wounds: Experimental and clinical evidence

Clinical Interventions in Aging

Volumn 3, Issue 2, 2008, Pages 263-272

  Romanelli, Marco ^a   Dini, Valentina ^a   Vowden, Peter ^b   Ågren, Magnus S ^c  

^a UNIVERSITY OF PISA   (Italy)

^b BRADFORD ROYAL INFIRMARY   (United Kingdom)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Amelogenin; Diabetic foot ulcers; Extracellular matrix; Pyoderma gangrenosum; Venous leg ulcers

Indexed keywords

AMELOGENIN; ANTIBIOTIC AGENT; PLACEBO; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; XELMA;

ANGIOGENESIS; BACTERIAL INFECTION; CLINICAL TRIAL; COMPRESSION THERAPY; DIABETIC FOOT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; LEG ULCER; PAIN ASSESSMENT; PERIODONTICS; PYODERMA GANGRENOSUM; REVIEW; ULCER HEALING; UNSPECIFIED SIDE EFFECT; WOUND; WOUND CARE;

AGED; AMELOGENIN; EXTRACELLULAR MATRIX PROTEINS; HUMANS; LEG ULCER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WOUND HEALING;

EID: 47849093483     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Acton C. 2007. The evaluation of an advanced treatment (Xelma) on hard-to-heal leg ulcers that have not responded to standard therapy [poster]. European Wound Management Association Conference, Glasgow, United Kingdom.
2. Ågren MS, Eaglstein WH, Ferguson MW, et al. 2000. Causes and effects ofthe chronic inflammation in venous leg ulcers. Acta Derm Venereol Suppl (Stockh), 210:3-17.
3. Ågren MS, Kleinman HK. 2007. Effect of amelogenins on angiogenesis ex vivo. Wound Rep Reg, 14:A74.
4. Ågren MS, Werthén M. 2007. The extracellular matrix in wound healing: a closer look at therapeutics for chronic wounds. Int J Low Extrem Wounds, 6:82-97.
5. Anderson I. 2006. Aetiology, assessment and management of leg ulcers. Wound Essentials, 1:20-36.
6. Badylak SF. 2002. The extracellular matrix as a scaffold for tissue reconstruction. Semin Cell Dev Biol, 13:377-83.
7. Bogaczewicz J, Dudek W, Wronski J, et al. 2005. [The role of matrix metalloproteinases in venous leg ulcers development]. Pol Merkur Lekarski, 19(113):686-92.
8. Chong CH, Carnes DL, Moritz AJ, et al. 2006. Human periodontal fibroblast response to enamel matrix derivative, amelogenin, and platelet-derived growth factor-BB. J Periodontol, 77:1242-52.
9. Dini V, Romanelli M, Bertone MS, et al. 2007. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody. Int J Low Extrem Wounds, 6:108-13.
10. Dini V, Bertone MS, Barbanera S, et al. 2007a. The use of amelogenin in pyoderma gangrenosum [poster]. European Wound Management Association Conference, Glasgow, United Kingdom.
11. Drinkwater SL, Burnand KG, Ding R, et al. 2003. Increased but ineffectual angiogenic drive in nonhealing venous leg ulcers. J Vasc Surg, 38:1106-12.
12. European Wound Management Association. 2002. Position Document: Pain at wound dressing changes. London: Medical Education Partnership.
13. Giannobile WV, Somerman MJ. 2003. Growth and amelogenin-like factors in periodontal wound healing. A systematic review. Ann Periodontol, 8:193-204.
14. Grayson RE, Yamakoshi Y, Wood EJ, et al. 2006. The effect of the amelogenin fraction of enamel matrix proteins on fibroblast-mediated collagen matrix reorganization. Biomaterials, 27:2926-33.
15. Hampton S, Kerr A, Bree-Aslan C. 2007. An evaluation of a matrix replacement treatment in intractable wounds. Poster presentation. European Wound Management Association Conference, Glasgow, United Kingdom.
16. Hartrick CT, Kovan JP, Shapiro S. 2003. The numeric rating scale for clinical pain measurement: a ratio measure. Pain Pract, 3:310-16.
17. Herouy Y, Trefzer D, Zimpfer U, et al. 2000. Matrix metalloproteinases and venous leg ulceration. Eur J Dermatol, 10:173-80.
18. Herrick SE, Sloan P, McGurk M, et al. 1992. Sequential changes in histologic pattern and extracellular matrix deposition during the healing or chronic venous ulcers. Am J Pathol, 141:1085-95.
19. Herrick SE, Ireland GW, Simon D, et al. 1996. Venous ulcer fibroblasts compared with normal fibroblasts show differences in collagen but not fibronectin production under both normal and hypoxic conditions. J Invest Dermatol, 106:187-93.
20. Hodde JP, Johnson CE. 2007. Extracellular matrix as a strategy for treating chronic wounds. Am J Clin Dermatol, 8:61-6.
21. Hofinan D, Ryan TJ, Arnold F, et al. 1997. Pain in venous leg ulcers. J Wound Care, 6:222-4.
22. Huldt-Nystrom T, Bonesronning JH, Dofour N, et al. 2007. Treatment of hard-to-heal chronic venous ulcerations with amelogenin. An update on the Norwegian experience [poster]. European Wound Management Association Conference, Glasgow, United Kingdom.
23. Kim NH, Tominaga K, Tanaka A. 2005. Analysis of eosinophilic round bodies formed after injection of enamel matrix derivative into the backs of rats. J Periodontol, 76:1934-41.
24. Mekkes JR, Loots MA, van der Wal AC, et al. 2003. Causes, investigation and treatment of leg ulceration. Br J Dermatol, 148:3 88-401.
25. Meuleneire F. 2007. A preliminary evaluation of an advanced therapy (Xelma®) for the treatment of hard to heal wounds: venous leg ulcers and diabetic foot ulcers [poster]. European Wound Management Association Conference, Glasgow, United Kingdom.
26. Mirastschijski U, Konrad D, Lundberg E, et al. 2004. Effects of a topical enamel matrix derivative on skin wound healing. Wound Rep Reg, 12:100-8.
27. Myhre AE, Lyngstadaas SP, Dahle ML, et al. 2006. Anti-inflammatory properties of enamel matrix derivative in human blood. J Periodontal Res, 41:208-13.
28. Phillips T, Machado F, Trout R, et al. 2000. Prognostic indicators in venous ulcers. J Am Acad Dermatol, 43:627-30.
29. Price P, Fogh K, Glynn C, et al. 2007. Managing painful chronic wounds: the Wound Pain Management Model. Int Wound J, 4(Suppl 1):4-15.
30. Romanelli M, Ellervee T, Jarve H, et al. 2006. Amelogenins (Xelma®) in hard-to-heal venous leg ulcers, an open regime investigation [poster]. European Wound Management Association Conference, Prague, Czech Republic.
31. Ryan S, Eager C, Sibbald RG. 2003. Venous leg ulcer pain. Ostomy Wound Manage, 49(4 Suppl):16-23.
32. Schlueter SR, Carnes DL, Cochran DL. 2007. In vitro effects of enamel matrix derivative on microvascular cells. J Periodontol, 78:141-51.
33. Schultz GS, Ladwig G, Wysocki A. 2005. Extracellular matrix: review of its roles in acute and chronic wounds [online]. Accessed June 13, 2007. URL: http://www.worldwidewounds.com/2005/august/.
34. Soon K, Acton C. 2006. Pain-induced stress: a barrier to wound healing. Wounds UK, 2:92-101.
35. Timmons J. 2006. Skin function and wound healing physiology. Wound Essentials, 1:8-17.
36. Ulrich D, Lichtenegger F, Unglaub F, et al. 2005. Effect of chronic wound exudates and MMP-2/-9 inhibitor on angiogenesis in vitro. Plast Reconstr Surg, 116:539-45.
37. Vowden P, Romanelli M, Peter R, et al. 2006. The effect of amelogenins (Xelma®) on hard-to-heal venous leg ulcers. Wound Rep Reg, 14:243-6.
38. Vowden P, Romanelli M, Price P. 2007. Effect of amelogenin extracellular matrix protein and compression on hard-to-heal venous leg ulcers. J Wound Care, 16:189-95.
39. Vowden K, Mcgowan J, Pilcher, M, et al. 2007a. Experience with the use of an amelogenin-based extracellular matrix substitute in the management of a variety of complex hard-to-heal chronic wounds [poster]. European Wound Management Association Conference, Glasgow, United Kingdom.
40. White R. 2006. Delayed wound healing: who, what, when and why? Nursing Standard, October 25(Suppl):47-54.
41. Winter GD. 1962. Formation of the scab and the rate of epithelialisation of superficial wounds in the skin of the young domestic pig. Nature, 193:293.
42. Young GR. 2003. Soft-tissue root coverage. Clinical rationale and case report. Dent Today, 22:134-9.
43. Young T. 2007. Assessment of wound pain: overview and a new initiative. Br J Nurs, 16:456-61.
44. Yuan K, Chen CL, Lin MT. 2003. Enamel matrix derivative exhibits angiogenic effect in vitro and in a murine model. J Clin Periodontol, 30:732-8.